Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
Vaxart (OTCQX: VXRT) announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 4:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vaxart (OTCQX: VXRT) announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 4:00 PM ET.
The virtual presentation will be webcast and available on the company investor relations website for 30 days following the event; management will also hold one-on-one meetings.
Details
News Market Reaction – VXRT
On Feb 18, the day this news came out, VXRT closed 1.65% below the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Conference dates
- February 25–26, 2026
- Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Presentation time
- 4:00pm ET
- Vaxart presentation on Wednesday, February 25, 2026
- Webcast availability
- 30 days
- Replay available on investor relations website after event
Historical Context
-
Phase 1 data for oral bivalent norovirus vaccine in lactating women and infants.
-
Announcement of presentation at Global BioInnovation Forum with senior leadership speakers.
-
Q3 2025 results, Dynavax collaboration, large Phase 2b COVID-19 trial enrollment and cash runway detail.
-
Planned Q3 earnings call and shareholder fireside chat to discuss results and take questions.
-
IDWeek 2025 presentation on next-generation oral bivalent norovirus vaccine Phase 1 data.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place virtually February 25-26, 2026.
Presentation Details:
Date and Time: Wednesday, February 25 at 4:00pm ET
Registration and Webcast: Click Here
The webcast will be available on the Company’s investor relations website at https://investors.vaxart.com for 30 days following the conclusion of the event.
The Company will participate in one-on-one meetings during the conference. Investors interested in meeting with management may reach out to their Oppenheimer representative.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com
(646) 871-8481
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.